New York Senate Passes Bill Restricting High-Concentration 7-OH Kratom Products

Why it matters

New York's bipartisan Senate vote signals a growing legislative consensus to regulate concentrated 7-hydroxymitragynine (7-OH) products separately from natural kratom leaf, potentially setting a national precedent for targeted regulation.

The big picture

As kratom-derived 7-OH products have proliferated in convenience stores and smoke shops, states across the country are grappling with how to respond. New York's approach—targeting products above a specific alkaloid concentration threshold—mirrors the FDA's July 2025 recommendation to schedule concentrated 7-OH as Schedule I, while stopping short of a wholesale kratom ban.

Key findings

• New York Senate Bill S.8925 passed June 2, 2026 with bipartisan support and now heads to the Assembly.
• The bill prohibits sale of 7-OH products exceeding 2% of total alkaloids or more than 1 milligram per serving.
• Violators face civil penalties of up to $500 for a first offense and $1,000 for subsequent offenses.
• The legislation explicitly targets synthetic and concentrated 7-OH products, not natural kratom leaf.
• Sponsor Senator Ryan cited growing addiction concerns and the lack of regulatory oversight for high-potency products.

What they say

"As these products become increasingly available in smoke shops, convenience stores, and online marketplaces, we have a responsibility to act before they create another public health crisis," said Senator Christopher J. Ryan. "These highly concentrated 7-OH products are being marketed with little oversight despite their powerful opioid-like effects and significant addiction concerns."

Bottom line

**New York's Senate has passed targeted legislation to cap 7-OH concentrations in kratom-derived products, establishing civil penalties for violations while preserving legal access to natural kratom leaf.**